Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 multicenter study of relugolix tablets in androgen-sensitive advanced prostate cancer
CTR20242496Phase 3Completed
- Sponsor
- Jiangxi Shanxiang Pharmaceutical
- Start
- Jul 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of tissue-plasminogen activator in prostate cancer (PCa), sponsored by Jiangxi Shanxiang Pharmaceutical. Started Jul 2024; status: completed.
02
Drugs
tissue-plasminogen activator
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on CTR20242496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242496.